A comparative pathophysiology diagram illustrating two mechanisms of mast cell activation and degranulation in hypersensitivity. The top panel depicts 'Allergic (IgE)-mediated hypersensitivity,' showing a multi-step process: initial sensitization where an allergen exposure leads to IgE antibodies binding to Fć̵R1 receptors on a Th2-type effector mast cell, followed by a second exposure where allergen cross-linking of the IgE-Fć̵R1 complex triggers degranulation. The bottom panel depicts 'Non-allergic (pseudoallergic)-mediated hypersensitivity,' highlighting that this pathway does not require prior sensitization. Instead, activation is triggered by direct interaction with Engineered Nanomaterials (ENMs) or anaphylatoxins from the complement system (C3a, C4a, C5a), leading directly to the release of intracellular granules. Visually, mast cells are shown as spherical purple cells with dense internal granules that are expelled into the extracellular space upon activation. The diagram serves as an educational tool to distinguish classic Type I hypersensitivity from direct mast cell triggers relevant to toxicology and immunology.

This pathophysiology diagram illustrates the two-phase immunological response in allergic rhinitis. The 'Early Phase' section details the sensitization process, starting with allergens such as pollen, dust mite debris, and animal dander being uptaken by dendritic cells. This triggers the activation of Th2 cells, which release cytokines and stimulate B lymphocytes via IL-3 and IL-4. These B cells differentiate into allergen-specific IgE-producing plasma cells that bind to basophils and mast cells. Upon allergen re-exposure, these sensitized cells undergo degranulation, leading to immediate histamine release. The 'Late Phase' section depicts the subsequent inflammatory cascade occurring hours later, characterized by the recruitment and infiltration of eosinophils, neutrophils, basophils, and lymphocytes. This influx results in the release of inflammatory substances, causing inflammatory mucosal swelling and culminating in clinical nasal blockage. The diagram serves as an educational tool for understanding Type I hypersensitivity and the transition from acute mast cell-mediated symptoms to chronic inflammatory tissue changes in the nasal mucosa.

This pathophysiology diagram illustrates the cellular and molecular sequence of events leading to allergic sensitization. The process begins with an allergen binding to a B cell receptor (IgM/IgG). The B cell acts as an antigen-presenting cell, displaying allergen peptides via MHC-II to a T follicular helper (TFH) cell's T cell receptor (TCR). This interaction is mediated by costimulation between CD40 on the B cell and CD40L on the TFH cell, alongside TFH secretion of Interleukin-4 (IL-4). These signals trigger class-switch recombination (CSR), causing the B cell to switch to IgE production. The IgE-switched B cell then undergoes differentiation into an IgE antibody-secreting cell (ASC). Secreted IgE antibodies circulate and bind to high-affinity IgE receptors (FcεRI) on the surface of basophils (BAS) and mast cells (MC). This binding, termed sensitization, primes these effector cells for future degranulation upon re-exposure to the specific allergen. The diagram highlights the critical role of T-B cell cross-talk in the pathogenesis of Type I hypersensitivity.

This pathophysiology diagram illustrates the biological mechanism of local allergic reactions induced by sublingual immunotherapy tablets (SLIT-T). The process begins with the release of allergens from SLIT-T into the oral epithelia. These allergens cross the epithelial barrier and bind to IgE antibodies complexed with FcεRI receptors on the surface of mast cells and basophils. This cross-linking triggers mast cell degranulation, releasing preformed granule mediators such as histamine and bradykinin. Simultaneously, it stimulates basophils to produce newly generated mediators, including platelet-activating factor (PAF), leukotrienes, and prostaglandins. The flowchart then maps these inflammatory mediators to their downstream physiological effects: nerve activation, increased vascular permeability, and vasodilation. Finally, the diagram lists the resulting clinical symptoms, such as pruritus, angioedema, irritation, sneezing, nasal congestion, and rhinorrhea. This educational resource summarizes the Type I hypersensitivity response specific to the sublingual route of allergen administration.